I K Moppett1, M Rowlands2, A M Mannings2, T C Marufu3, O Sahota4, J Yeung5. 1. Anaesthesia and Critical Care Research Group, Division of Clinical Neuroscience, Queen's Medical Centre, University of Nottingham, Nottingham, UK. 2. Department of Anaesthesia, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 3. Department of Healthcare of Older Life, Nottingham University Hospitals NHS Trust, Nottingham, UK. 4. Nottingham University Hospitals NHS Trust, Nottingham, UK. 5. Warwick Medical School, University of Warwick, Warwick, UK.
Abstract
BACKGROUND:anaemia following hip fracture is common and associated with worse outcomes. Intravenous iron is a potential non-transfusion treatment for this anaemia and has been found to reduce transfusion rates in previous observational studies. There is good evidence for its use in elective surgical populations. OBJECTIVE: to examine the impact of intravenous iron on erythropoiesis following hip fracture. DESIGN: two-centre, assessor-blinded, randomised, controlled trial of patients with primary hip fracture and no contra-indications to intravenous iron. METHOD: the intervention group received three doses of 200 mg iron sucrose over 30 min (Venofer, Vifor Pharma, Bagshot Park, UK) on three separate days. Primary outcome was reticulocyte count at day 7 after randomisation. Secondary outcomes included haemoglobin concentration, complications and discharge destination. Eighty participants were randomised. RESULTS: there was a statistically significantly greater absolute final reticulocyte count in the iron group (89.4 (78.9-101.3) × 109 cellsl-1 (n = 39) vs. the control (72.2 (63.9-86.4)) × 109 cellsl-1 (n = 41); P = 0.019; (mean (95% confidence intervals) of log-transformed data). There were no differences in final haemoglobin concentration (99.9 (95.7-104.2) vs. 102.0 (98.7-105.3) P = 0.454) or transfusion requirements in the first week (11 (28%) vs. 12 (29%); P = 0.899). Functional and safety outcomes were not different between the groups. CONCLUSIONS: although intravenous iron does stimulate erythropoiesis following hip fracture in older people, the effect is too small and too late to affect transfusion rates. Trial Registry Numbers: ISRCTN:76424792; EuDRACT: 2011-003233-34.
RCT Entities:
BACKGROUND:anaemia following hip fracture is common and associated with worse outcomes. Intravenous iron is a potential non-transfusion treatment for this anaemia and has been found to reduce transfusion rates in previous observational studies. There is good evidence for its use in elective surgical populations. OBJECTIVE: to examine the impact of intravenous iron on erythropoiesis following hip fracture. DESIGN: two-centre, assessor-blinded, randomised, controlled trial of patients with primary hip fracture and no contra-indications to intravenous iron. METHOD: the intervention group received three doses of 200 mg iron sucrose over 30 min (Venofer, Vifor Pharma, Bagshot Park, UK) on three separate days. Primary outcome was reticulocyte count at day 7 after randomisation. Secondary outcomes included haemoglobin concentration, complications and discharge destination. Eighty participants were randomised. RESULTS: there was a statistically significantly greater absolute final reticulocyte count in the iron group (89.4 (78.9-101.3) × 109 cells l-1 (n = 39) vs. the control (72.2 (63.9-86.4)) × 109 cells l-1 (n = 41); P = 0.019; (mean (95% confidence intervals) of log-transformed data). There were no differences in final haemoglobin concentration (99.9 (95.7-104.2) vs. 102.0 (98.7-105.3) P = 0.454) or transfusion requirements in the first week (11 (28%) vs. 12 (29%); P = 0.899). Functional and safety outcomes were not different between the groups. CONCLUSIONS: although intravenous iron does stimulate erythropoiesis following hip fracture in older people, the effect is too small and too late to affect transfusion rates. Trial Registry Numbers: ISRCTN:76424792; EuDRACT: 2011-003233-34.
Authors: Silas Zacharias Clemmensen; Kristian H Kragholm; Dorte Melgaard; Lene T Hansen; Johannes Riis; Christian Cavallius; Marianne M Mørch; Maria Lukács Krogager Journal: J Orthop Surg Res Date: 2021-05-18 Impact factor: 2.359
Authors: Akshay A Shah; Killian Donovan; Claire Seeley; Edward A Dickson; Antony J R Palmer; Carolyn Doree; Susan Brunskill; Jack Reid; Austin G Acheson; Anita Sugavanam; Edward Litton; Simon J Stanworth Journal: JAMA Netw Open Date: 2021-11-01
Authors: Jae Hyun Kwon; Yong Hyun Cho; Won Jang; Sun Hee Kim; Hyun Cheol Ko; Woo Hyeong Ko; Young Do Kim Journal: Medicine (Baltimore) Date: 2022-09-02 Impact factor: 1.817